Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155749 · ClinicalTrials.gov registry record · Phase 1
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
A Phase 1 study of Relapsed and Refractory Multiple Myeloma, sponsored by Kite, A Gilead Company.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT04155749: Active Phase 1 study of Relapsed and Refractory Multiple Myeloma, sponsored by Kite, A Gilead Company.
NCT04155749 is a Phase 1 study of Relapsed and Refractory Multiple Myeloma that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155749, a Phase 1 study of Relapsed and Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Kite, A Gilead Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Conditions Studied
Interventions
- DRUG anitocabtagene-autoleucel
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Illinois
- Advanced Cellular Therapeutics Facility, DCAM 0800A - Chicago
Wisconsin
- Froedtert Hospital/Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What the registry record for NCT04155749 still lists
NCT04155749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Relapsed and Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which anitocabtagene-autoleucel is the first listed.
NCT04155749 reports a single indexed study location in Massachusetts, Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04155749 about?
NCT04155749 is a clinical study titled "Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma". Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
What is the current status of trial NCT04155749?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-12-23. Estimated completion is 2027-05.
What conditions does trial NCT04155749 study?
This clinical trial studies the following conditions: Relapsed and Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04155749?
The interventions under investigation include: anitocabtagene-autoleucel (DRUG).
Who is sponsoring clinical trial NCT04155749?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04155749 being conducted?
This trial has 4 study locations across Illinois, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed and Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04155749's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI